Surgery Partners, Inc. (SGRY) Stock Analysis and Metrics

Surgery Partners

NASDAQ: SGRY

$16.00 ▼ -0.64 (-3.85%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.13 Bn

P/E21.95

P/S0.64

Div. Yield0.10

ROIC (Qtr)0.00

Total Debt (Qtr)3.71 Bn

Revenue Growth (1y) (Qtr)4.50

Add ratio to table…

About

Surgery Partners, Inc. owns and operates a national network of surgical facilities and ancillary services. The company delivers an integrated outpatient delivery model that provides high quality cost effective surgical and related ancillary care to patients and physicians.

The company generates revenue primarily from facility fees for health care services performed in its surgical facilities, which are included in patient service revenues. It also earns management fees from non consolidated surgical facilities for management services provided, reported as other service revenues. Revenue is received from private insurance payors, government programs such as Medicare and Medicaid, self pay patients and other sources.

The company operates through the following segment: Surgical Facilities.

• Surgical Facilities includes the operation of ambulatory surgery centers, short stay surgical hospitals, anesthesia services, urgent care facilities and multi specialty physician practices. The segment provides nonemergency surgical procedures across specialties such as orthopedics and pain management, ophthalmology, gastroenterology and general surgery.

Surgery Partners, Inc. is one of the largest and fastest growing surgical services businesses in the United States. The company operates more than 200 locations across 30 states, giving it significant scale and national prominence. Its competitive advantages include a strong reputation, an integrated outpatient delivery model, a physician engagement strategy that attracts independent physicians, and strategic partnerships with health care systems and private insurance payors. Key competitors in the industry include HCA Healthcare, Inc., AMSURG Corp., Tenet Healthcare Corporation and Optum, Inc.

The company serves patients undergoing surgical procedures and physicians who use its facilities for cases. Its revenue is derived from private insurance payors, government programs such as Medicare and Medicaid, self pay patients and other sources.

Investment Thesis

▲ Bull case

Surgery Partners is strategically positioned to capitalize on the accelerating shift of high-acuity procedures to outpatient settings, driven by both technological adoption and favorable regulatory changes, which the market is underestimating. The company’s investment in surgical robotics—now totaling 73 systems across its platform—is enabling safer and more efficient performance of complex procedures like total joints, which grew 14.6% year-over-year in the quarter. This trend is not merely incremental; it reflects a structural shift where physicians, incentivized by the removal of the Medicare inpatient-only list, are increasingly migrating their higher-revenue cases to ASCs. Management noted that technology remains a barrier in some specialties, but emphasized that new robotic systems and payer partnerships are actively addressing this gap. As these capabilities scale, Surgery Partners can capture higher reimbursement rates per case while maintaining lower cost structures than hospitals, directly expanding its addressable market and improving case mix. The market appears to be pricing in only modest case growth, but fails to account for the compounding effect of acuity-driven revenue expansion, which could drive same-facility revenue growth well above the guided 3%-plus rate as robotic adoption and physician recruitment in high-margin specialties like orthopedics and vascular continue to accelerate.
The company’s portfolio optimization initiative represents a significant, underappreciated catalyst for deleveraging and free cash flow enhancement, with potential to accelerate shareholder returns beyond current expectations. Surgery Partners is in advanced discussions to divest or deconsolidate one larger surgical hospital market—a non-core asset with broader services than its short-stay focus—and targets a mid-2026 announcement. This transaction is not merely a cost-saving move; it is designed to reduce leverage (currently 4.3x net debt/EBITDA under credit agreement) and improve free cash flow conversion by shedding capital-intensive, lower-margin assets. Management explicitly linked this effort to unlocking financial benefit through reduced leverage and better cash flow, noting the Board’s active engagement. The market appears to be treating this as a peripheral effort, but the timing—mid-2026—aligns with the typical inflection point when such transactions begin to materially impact earnings in the second half of the year. Given the fragmentation of the ASC landscape and Surgery Partners’ scale advantage, successful execution could not only de-risk the balance sheet but also redeploy capital into higher-return de novos and acquisitions, creating a virtuous cycle of growth and margin expansion that is not reflected in current valuation multiples.
Physician recruitment and retention are emerging as a durable, self-reinforcing growth engine that the market is overlooking due to short-term volatility in case growth metrics. During Q1, Surgery Partners added approximately 140 physicians, with strong concentrations in orthopedics, ophthalmology, and GI—specialties tied to higher-acuity, higher-revenue procedures. Critically, the company noted that this recruiting class generates higher net revenue per physician than the prior year’s cohort, indicating improving quality of additions. While recruitment is traditionally back-end loaded, the early start and focus on MSK and robotics-enabled specialties suggest a strategic shift toward attracting physicians who bring not just volume, but acuity and technological adoption. This is further amplified by the de novo pipeline—five centers expected to open later this year, seven more in the pipeline—each heavily weighted toward MSK and designed to integrate robotic systems from inception. As these physicians ramp and new facilities mature, the company is poised to benefit from a compounding effect: each new recruit increases case volume, drives technology utilization, and enhances facility-level profitability. The market’s focus on the modest 0.6% same-facility case growth in Q1 ignores this underlying quality improvement and the long-term payoff from targeted recruitment, which could sustainably elevate organic growth beyond historical averages as the year progresses.

Surgery Partners is strategically positioned to capitalize on the accelerating shift of high-acuity procedures to outpatient settings, driven by both technological adoption and favorable regulatory changes, which the market is underestimating. The company’s investment in surgical robotics—now totaling 73 systems across its platform—is enabling safer and more efficient performance of complex procedures like total joints, which grew 14.6% year-over-year in the quarter. This trend is not merely incremental; it reflects a structural shift where physicians, incentivized by the removal of the Medicare inpatient-only list, are increasingly migrating their higher-revenue cases to ASCs. Management noted that technology remains a barrier in some specialties, but emphasized that new robotic systems and payer partnerships are actively addressing this gap. As these capabilities scale, Surgery Partners can capture higher reimbursement rates per case while maintaining lower cost structures than hospitals, directly expanding its addressable market and improving case mix. The market appears to be pricing in only modest case growth, but fails to account for the compounding effect of acuity-driven revenue expansion, which could drive same-facility revenue growth well above the guided 3%-plus rate as robotic adoption and physician recruitment in high-margin specialties like orthopedics and vascular continue to accelerate.
The company’s portfolio optimization initiative represents a significant, underappreciated catalyst for deleveraging and free cash flow enhancement, with potential to accelerate shareholder returns beyond current expectations. Surgery Partners is in advanced discussions to divest or deconsolidate one larger surgical hospital market—a non-core asset with broader services than its short-stay focus—and targets a mid-2026 announcement. This transaction is not merely a cost-saving move; it is designed to reduce leverage (currently 4.3x net debt/EBITDA under credit agreement) and improve free cash flow conversion by shedding capital-intensive, lower-margin assets. Management explicitly linked this effort to unlocking financial benefit through reduced leverage and better cash flow, noting the Board’s active engagement. The market appears to be treating this as a peripheral effort, but the timing—mid-2026—aligns with the typical inflection point when such transactions begin to materially impact earnings in the second half of the year. Given the fragmentation of the ASC landscape and Surgery Partners’ scale advantage, successful execution could not only de-risk the balance sheet but also redeploy capital into higher-return de novos and acquisitions, creating a virtuous cycle of growth and margin expansion that is not reflected in current valuation multiples.
Physician recruitment and retention are emerging as a durable, self-reinforcing growth engine that the market is overlooking due to short-term volatility in case growth metrics. During Q1, Surgery Partners added approximately 140 physicians, with strong concentrations in orthopedics, ophthalmology, and GI—specialties tied to higher-acuity, higher-revenue procedures. Critically, the company noted that this recruiting class generates higher net revenue per physician than the prior year’s cohort, indicating improving quality of additions. While recruitment is traditionally back-end loaded, the early start and focus on MSK and robotics-enabled specialties suggest a strategic shift toward attracting physicians who bring not just volume, but acuity and technological adoption. This is further amplified by the de novo pipeline—five centers expected to open later this year, seven more in the pipeline—each heavily weighted toward MSK and designed to integrate robotic systems from inception. As these physicians ramp and new facilities mature, the company is poised to benefit from a compounding effect: each new recruit increases case volume, drives technology utilization, and enhances facility-level profitability. The market’s focus on the modest 0.6% same-facility case growth in Q1 ignores this underlying quality improvement and the long-term payoff from targeted recruitment, which could sustainably elevate organic growth beyond historical averages as the year progresses.

▼ Bear case

Surgery Partners faces persistent and underappreciated payer mix pressures that could erode profitability despite management’s optimism, particularly as commercial reimbursement rates face sustained downward pressure from employer-driven cost containment and Medicare Advantage plan design shifts. While the company acknowledged modest payer mix pressure in Q1 and noted moderation from 2025 levels, it failed to address the structural nature of these headwinds—namely, that commercial payers are increasingly steering patients toward lower-cost settings through narrow networks, prior authorization rigor, and site-of-service policies that favor hospitals over ASCs for certain procedures. Management’s focus on recovering commercial market share assumes payer willingness to negotiate, but overlooked the growing trend of employers and insurers imposing stricter utilization controls that limit ASC eligibility regardless of physician preference. Furthermore, the company’s reliance on commercial mix improvement to offset Medicaid cuts and provider taxes ignores the fact that Medicare Advantage enrollment continues to grow, often bringing lower reimbursement rates than traditional Medicare. Without meaningful detail on contracted rate trends or specific payer contract renewals, the market may be overestimating the company’s ability to stabilize or grow commercial revenue per case, leaving margin expansion vulnerable to external forces beyond operational control.
The company’s capital allocation strategy, particularly its M&A pipeline and de novo development timeline, carries execution risk that could delay expected returns and exacerbate leverage concerns, a risk the market is not sufficiently pricing in. Surgery Partners reiterated its target of deploying approximately $200 million annually in M&A but deployed only $4 million in Q1, citing a “modest start” and fickle timing. While management expressed confidence in a healthy pipeline, it provided no concrete details on deal size, valuation multiples, or regulatory hurdles—especially critical given increased scrutiny from the FTC and DOJ on healthcare consolidation. The de novo pipeline, while promising, requires 12–18 months to syndicate and build, followed by another year to reach cash flow breakeven, meaning the five centers expected to open later this year will not contribute meaningfully to EBITDA until 2027 at the earliest. This extended timeline undermines the near-term growth narrative, especially as interest expenses rose $7 million year-over-year due to swap expiration and higher rates, pressuring free cash flow. With net leverage at 4.3x and GAAP net debt to adjusted EBITDA at 5.1x, any delay in M&A or de novo ramp-up could force reliance on earnings growth alone to deleverage—a challenging prospect if outpatient procedure volumes fail to accelerate as anticipated, leaving the company vulnerable to covenant pressure or forced asset sales at suboptimal valuations.
Operational metrics reveal a growing divergence between case volume and revenue per case that suggests the company’s growth strategy may be losing momentum in its core lower-acuity markets, a trend management downplayed as temporary but which could signal deeper structural challenges. Same-facility case growth was only 0.6% in Q1, attributed partially to weather-related disruptions (estimated at 40 basis points), but even adjusting for this, growth remained well below the 2%-3% long-term algorithm. Management emphasized that higher-acuity segments like vascular and orthopedics showed strength, yet failed to quantify how much of the 4.4% same-facility revenue growth was driven by rate increases versus case volume—implying that revenue growth may be increasingly reliant on pricing power rather than organic volume expansion. This is concerning given the company’s stated goal of expanding surgical case volumes while shifting toward higher acuity; if case growth remains stagnant, the sustainability of revenue gains becomes questionable, particularly in markets where payers are resisting rate hikes. Furthermore, the reliance on physician recruiting to drive future growth assumes these new physicians will generate incremental volume, but if they are merely shifting existing cases from hospitals to ASCs without expanding the overall procedural pie, the net benefit to Surgery Partners could be limited. The market may be misinterpreting modest revenue growth as signs of recovery, when in fact it could reflect a stagnant base case mix increasingly dependent on inflationary rate adjustments rather than true volume-driven expansion.

Surgery Partners faces persistent and underappreciated payer mix pressures that could erode profitability despite management’s optimism, particularly as commercial reimbursement rates face sustained downward pressure from employer-driven cost containment and Medicare Advantage plan design shifts. While the company acknowledged modest payer mix pressure in Q1 and noted moderation from 2025 levels, it failed to address the structural nature of these headwinds—namely, that commercial payers are increasingly steering patients toward lower-cost settings through narrow networks, prior authorization rigor, and site-of-service policies that favor hospitals over ASCs for certain procedures. Management’s focus on recovering commercial market share assumes payer willingness to negotiate, but overlooked the growing trend of employers and insurers imposing stricter utilization controls that limit ASC eligibility regardless of physician preference. Furthermore, the company’s reliance on commercial mix improvement to offset Medicaid cuts and provider taxes ignores the fact that Medicare Advantage enrollment continues to grow, often bringing lower reimbursement rates than traditional Medicare. Without meaningful detail on contracted rate trends or specific payer contract renewals, the market may be overestimating the company’s ability to stabilize or grow commercial revenue per case, leaving margin expansion vulnerable to external forces beyond operational control.
The company’s capital allocation strategy, particularly its M&A pipeline and de novo development timeline, carries execution risk that could delay expected returns and exacerbate leverage concerns, a risk the market is not sufficiently pricing in. Surgery Partners reiterated its target of deploying approximately $200 million annually in M&A but deployed only $4 million in Q1, citing a “modest start” and fickle timing. While management expressed confidence in a healthy pipeline, it provided no concrete details on deal size, valuation multiples, or regulatory hurdles—especially critical given increased scrutiny from the FTC and DOJ on healthcare consolidation. The de novo pipeline, while promising, requires 12–18 months to syndicate and build, followed by another year to reach cash flow breakeven, meaning the five centers expected to open later this year will not contribute meaningfully to EBITDA until 2027 at the earliest. This extended timeline undermines the near-term growth narrative, especially as interest expenses rose $7 million year-over-year due to swap expiration and higher rates, pressuring free cash flow. With net leverage at 4.3x and GAAP net debt to adjusted EBITDA at 5.1x, any delay in M&A or de novo ramp-up could force reliance on earnings growth alone to deleverage—a challenging prospect if outpatient procedure volumes fail to accelerate as anticipated, leaving the company vulnerable to covenant pressure or forced asset sales at suboptimal valuations.
Operational metrics reveal a growing divergence between case volume and revenue per case that suggests the company’s growth strategy may be losing momentum in its core lower-acuity markets, a trend management downplayed as temporary but which could signal deeper structural challenges. Same-facility case growth was only 0.6% in Q1, attributed partially to weather-related disruptions (estimated at 40 basis points), but even adjusting for this, growth remained well below the 2%-3% long-term algorithm. Management emphasized that higher-acuity segments like vascular and orthopedics showed strength, yet failed to quantify how much of the 4.4% same-facility revenue growth was driven by rate increases versus case volume—implying that revenue growth may be increasingly reliant on pricing power rather than organic volume expansion. This is concerning given the company’s stated goal of expanding surgical case volumes while shifting toward higher acuity; if case growth remains stagnant, the sustainability of revenue gains becomes questionable, particularly in markets where payers are resisting rate hikes. Furthermore, the reliance on physician recruiting to drive future growth assumes these new physicians will generate incremental volume, but if they are merely shifting existing cases from hospitals to ASCs without expanding the overall procedural pie, the net benefit to Surgery Partners could be limited. The market may be misinterpreting modest revenue growth as signs of recovery, when in fact it could reflect a stagnant base case mix increasingly dependent on inflationary rate adjustments rather than true volume-driven expansion.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	87.94 Bn	11.25	1.15	48.02 Bn
2	CHE	Chemed Corp	18.08 Bn	51.68	7.12	0.09 Bn
3	THC	Tenet Healthcare Corp	16.59 Bn	9.74	0.77	13.21 Bn
4	DVA	Davita Inc.	15.37 Bn	14.02	1.10	10.63 Bn
5	EHC	Encompass Health Corp	10.07 Bn	654.20	1.66	2.57 Bn
6	ENSG	Ensign Group, Inc	9.52 Bn	27.18	1.81	0.14 Bn
7	UHS	Universal Health Services Inc	9.19 Bn	6.05	0.52	4.71 Bn
8	PACS	PACS Group, Inc.	6.96 Bn	28.55	1.28	0.05 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password